PRESTIGE CONSMR (PBH)
(Delayed Data from NYSE)
$70.47 USD
+0.33 (0.47%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $70.54 +0.07 (0.10%) 4:28 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Company Summary
Based in New York, Prestige Consumer Healthcare Inc. and its subsidiaries develop, manufacture, market, sell and distributes over-the-counter (“OTC”) healthcare and household cleaning products in United States, Canada, Australia and certain other international markets. The company provides its products to mass merchandisers as well as drug, food, dollar, convenience, and club stores. Also, Prestige Consumer Healthcare operates through the e-commerce channel.
Following the divestiture of Household Cleaning segment in July 2018, Prestige Consumer reports operating results through two segments: North American OTC Healthcare (86.3% of fiscal 2023 revenues, up 0.6%) and International OTC ...
Company Summary
Based in New York, Prestige Consumer Healthcare Inc. and its subsidiaries develop, manufacture, market, sell and distributes over-the-counter (“OTC”) healthcare and household cleaning products in United States, Canada, Australia and certain other international markets. The company provides its products to mass merchandisers as well as drug, food, dollar, convenience, and club stores. Also, Prestige Consumer Healthcare operates through the e-commerce channel.
Following the divestiture of Household Cleaning segment in July 2018, Prestige Consumer reports operating results through two segments: North American OTC Healthcare (86.3% of fiscal 2023 revenues, up 0.6%) and International OTC Healthcare (13.7%, up 29.4%).
Some of the major brands under North American and International OTC Healthcare include products like BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat treatments and mouth pain products, Clear Eyes eye care products, Compound Wwart removers, Dramamine Non-Drowsy naturals, Pedia-Lax pediatric laxatives, Efferdent denture cleansers, Luden's throat drops, Debrox for ear wax removal, Hydralyte for oral rehydration, Fess nasal saline spray and Gaviscon for upset stomach remedies.
Prestige Consumer Healthcare remains focused on certain core strategies to achieve success. These include developing efficient sales, marketing and advertising plans; undertaking successful integration of acquired brands; launching innovative products; setting up third-party production and distributions; keeping pace with the advanced technology and competitive moves; and continuing with geographic expansions (both domestic and international).
Prestige Consumer Healthcare’s well-known acquisitions include Akorn Operating Company's consumer brands in July 2021; Fleet in January 2017; DenTek Holdings, Inc in 2016; Hydralyte in 2015 and BC & Goody’s in 2012. Fleet is one of the largest transactions made by Healthcare. Such buyouts are expected to radically enhance the company’s growth prospects.
General Information
Prestige Consumer Healthcare Inc
660 WHITE PLAINS ROAD
TARRYTOWN, NY 10591
Phone: 914-524-6800
Fax: 302-674-5266
Web: http://www.prestigebrands.com
Email: irinquiries@prestigebrands.com
Industry | Medical - Products |
Sector | Medical |
Fiscal Year End | March |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/14/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.14 |
Current Year EPS Consensus Estimate | 4.33 |
Estimated Long-Term EPS Growth Rate | 8.00 |
Exp Earnings Date | 5/14/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 70.14 |
52 Week High | 75.31 |
52 Week Low | 55.96 |
Beta | 0.52 |
20 Day Moving Average | 197,401.20 |
Target Price Consensus | 73.33 |
4 Week | -3.34 |
12 Week | 12.17 |
YTD | 14.57 |
4 Week | 0.61 |
12 Week | 9.01 |
YTD | 8.25 |
Shares Outstanding (millions) | 49.65 |
Market Capitalization (millions) | 3,482.40 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 15.22 |
Trailing 12 Months | 16.47 |
PEG Ratio | 1.90 |
vs. Previous Year | 1.92% |
vs. Previous Quarter | -0.93% |
vs. Previous Year | 2.62% |
vs. Previous Quarter | -1.25% |
Price/Book | 2.17 |
Price/Cash Flow | 14.00 |
Price / Sales | 3.07 |
3/31/24 | NA |
12/31/23 | 14.09 |
9/30/23 | 13.82 |
3/31/24 | NA |
12/31/23 | 6.39 |
9/30/23 | 6.17 |
3/31/24 | NA |
12/31/23 | 3.09 |
9/30/23 | 2.99 |
3/31/24 | NA |
12/31/23 | 1.92 |
9/30/23 | 1.75 |
3/31/24 | NA |
12/31/23 | 18.83 |
9/30/23 | 18.86 |
3/31/24 | NA |
12/31/23 | -7.11 |
9/30/23 | -7.26 |
3/31/24 | NA |
12/31/23 | -8.01 |
9/30/23 | -8.19 |
3/31/24 | NA |
12/31/23 | 32.26 |
9/30/23 | 30.95 |
3/31/24 | NA |
12/31/23 | 3.16 |
9/30/23 | 3.12 |
3/31/24 | NA |
12/31/23 | 0.75 |
9/30/23 | 0.82 |
3/31/24 | NA |
12/31/23 | 42.84 |
9/30/23 | 45.13 |